Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 3/20 | 0.63 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.56 |
| ▸ | ABHD6 | Q9BV23 | 6/20 | 0.54 |
| ▸ | ESR1 | P03372 | 2/20 | 0.53 |
| ▸ | LIPE | Q05469 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.45 |
| ▸ | MGLL | Q99685 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3875381 | 0.91 | ABHD6 (0.53) | ESR2NR1H2ABHD6ESR1LIPE | |
| SCHEMBL14781510 | 0.87 | ESR2 (0.67) | ESR2NR1H2ABHD6ESR1MGLL | |
| SCHEMBL25317295 | 0.84 | ESR2 (0.63) | ESR2NR1H2ABHD6ESR1MGLL | |
| SCHEMBL21659712 | 0.84 | ESR2 (0.63) | ESR2NR1H2ABHD6ESR1SCN9A | |
| SCHEMBL31425341 | 0.84 | ESR2 (0.63) | ESR2NR1H2ABHD6ESR1MGLL | |
| SCHEMBL22755687 | 0.83 | ESR2 (0.62) | ESR2NR1H2ABHD6ESR1MGLL | |
| SCHEMBL31014031 | 0.83 | ESR2 (0.62) | ESR2NR1H2ABHD6ESR1MGLL | |
| SCHEMBL13538188 | 0.83 | ESR2 (0.62) | ESR2NR1H2ABHD6ESR1MGLL | |
| SCHEMBL15755296 | 0.83 | ESR2 (0.72) | ESR2NR1H2ABHD6ESR1MAPT | |
| SCHEMBL29368645 | 0.83 | ESR2 (0.72) | ESR2NR1H2ABHD6ESR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-18 | — | — | US | disclosed |
| EP-3053917-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nissan Chemical Industries, Ltd. (JP) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015050212-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 日産化学工業株式会社 | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1I, CACNA1G, CACNA1H | ESR2 3752/4885NR1H2 2325/4885ABHD6 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.